



World Organisation
for Animal Health
Founded in 1924


中华人民共和国农业农村部
Ministry of Agriculture and Rural Affairs of the People's Republic of China

Control of human brucellosis in China

Dr. Hai Jiang

National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases


Chinese Center for Disease Control and Prevention





● Outlines

- **History of human brucellosis surveillance**
- Epidemiological characteristics of human brucellosis
- Strategies of control and prevention of human brucellosis
- Etiology surveillance of human brucellosis



Milestone events of human Brucellosis surveillance



- # Outlines

- History of human brucellosis surveillance
- **Epidemiological characteristics of human brucellosis**
- Strategies of control and prevention of human brucellosis
- Vision of human brucellosis surveillance

Global Estimate of Human Brucellosis Incidence

Christopher G. Laine, Valen E. Johnson, H. Morgan Scott, Angela M. Arenas-Gamboa

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 29, No. 9, September 2023

>2.1 million







Figure 5. Heatmaps of regional annual incidence of human brucellosis estimated per 1 million population at risk. Each region has a different scale for incidence per 1 million population at risk. Heatmaps are intended to represent transnational zones that require priority control or surveillance initiative, not to represent the risk of individual countries. The heat scale shows high risk to low risk; yellow to blue. A) Africa: average risk is ≈ 750 new cases per million; high is $>3,000$. B) Asia: average risk is ≈ 500 new cases per million; high is $\geq 4,000$. C) Americas: average risk is ≈ 20 new cases per million; high is ≥ 75 . D) Europe: average risk is ≈ 10 new cases per million; high ≥ 100 .

95 sentinels from 31 provinces in 2012







Time series of monthly cases, 2005-2014



Geographic distribution of reported cases in 2023



Reported human brucellosis cases and annual incidence rate ,1950-2023



Incidence rate from the top six provinces, 2013—2023

- **Outlines**
 - History of human brucellosis surveillance
 - Epidemiological characteristics of human brucellosis
 - **Strategies of control and prevention of human brucellosis**
 - Vision of human brucellosis surveillance



Five stages of brucellosis prevention and control in China

12




Fig. 1 Aggregated number of cases (blue bars) and annual incidence rate (orange line) per 100 000 residents, 1950–2019

Key aims for human brucellosis (2023-2030)

**Cure rate in
patients with
acute period
(>85%)**

**Reduce
Chronic Damage**

High-risk population KAP: >95%

Case management: >95%



9 Key Measures

Surveillance

- The active surveillance of brucellosis should be strengthened to detect cases early.

High-risk population screening

- at least once a year.
- Screening coverage should not be less than 70% in 2026 and not less than 90% in 2030.

Epidemic investigation

- Two-way tracing between suspected infected humans and animals



9 Key Measures

Special survey

- Based on the epidemic characteristics to provide a basis for formulating scientific prevention and control strategies.

Standardized diagnosis, treatment and management of cases

- Guidelines for Brucellosis Diagnosis and Treatment
- Electronic pill boxes, family doctor APP

Health education and behavior intervention

- Social mobilization
- KAP



9 Key Measures

Information Sharing

- early warning
- risk assessment

Rural Environment Governance

- One Health

Effectiveness Evaluation

- benefit cost
- adjustment

中国动物疫病预防控制中心
(农业农村部屠宰技术中心) 文件
中国疾病预防控制中心

疫控卫〔2022〕172 号

中国动物疫病预防控制中心
中国疾病预防控制中心关于印发
《布鲁氏菌病防控技术要点(第一版)》的通知

各省、自治区、直辖市及计划单列市动物疫病预防控制机构、动物卫生监督机构、疾病预防控制中心,新疆生产建设兵团畜牧兽医工作总站、疾病预防控制中心:

目前我国人间畜间布鲁氏菌病防控形势严峻复杂,针对当前布鲁氏菌病流行态势、防控难点和实际需求,中国动物疫病预防控制中心联合中国疾病预防控制中心,组织编写了《布鲁氏菌病防

— 1 —

医疗应急司

主站首页 | 首页 | 关于我们

最新信息

您现在所在位置: 首页 > 最新信息

《关于印发鼠疫等传染病诊疗方案(2023年版)的通知》解读

发布时间: 2023-12-28 来源: 医疗应急司



近年来,我委制定印发了多种常见及新发、突发传染病诊疗方案,对有效处置相关传染病疫情发挥了重要作用。为进一步提高各类传染病规范化、同质化诊疗水平,指导各级医疗机构规范做好传染病医疗救治工作,我委会同国家中医药局,对部分法定传染病及其他常见传染病诊疗情况进行了梳理,结合近年来相关传染病流行、发病情况及研究成果、诊疗技术进展,组织制(修)订了鼠疫、霍乱、炭疽、细菌性痢疾、流行性脑脊髓膜炎、百日咳、猩红热、布鲁氏菌病、黑热病、水痘、发热伴血小板减少综合征等传染病诊疗方案,形成了相关传染病诊疗方案(2023年版)。诊疗方案主要包括相关传染病的病原学、流行病学、临床表现、实验室及影像学检查、诊断、鉴别诊断、治疗和预防措施等,供各地参照执行。


相关链接: 关于印发鼠疫等传染病诊疗方案(2023年版)的通知

- **Outlines**
 - History of human brucellosis surveillance
 - Epidemiological characteristics of human brucellosis
 - Strategies of control and prevention of human brucellosis
 - **Etiology surveillance of human brucellosis**



- Identifying outbreaks
- Tracing pathogen transmission
- Discovering new nodes or ways of transmission
- Identifying new clones or clades
- Regional and global surveillance networks

Biao Kan et al. Transforming bacterial disease surveillance and investigation using whole-genome sequence to probe the trace. Front. Med., 2018, 12(1): 23-33





ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1999, p. 194–195

0066-4804/99/\$04.00+0

Copyright © 1999, American Society for Microbiology. All Rights Reserved.

Vol. 43, No. 1

In Vitro Activities of Six New Fluoroquinolones against *Brucella melitensis*

IGNACIO TRUJILLANO-MARTÍN,¹ ENRIQUE GARCÍA-SÁNCHEZ,¹ ISAÍAS MONTES MARTÍNEZ,²
MARÍA JOSÉ FRESNADILLO,¹ JOSÉ ELÍAS GARCÍA-SÁNCHEZ,¹
AND JOSÉ ÁNGEL GARCÍA-RODRÍGUEZ^{1*}

*Departamento de Microbiología y Parasitología, Hospital Universitario, Salamanca,¹ and
Unidad de Microbiología, Hospital Virgen del Puerto, Plasencia, Cáceres,² Spain*

Received 24 June 1998/Returned for modification 13 August 1998/Accepted 23 October 1998

We have tested the in vitro activities of eight fluoroquinolones against 160 *Brucella melitensis* strains. The most active was sitafloxacin (MIC at which 90% of the isolates are inhibited [MIC₉₀], 0.12 µg/ml). In decreasing order, the activities (MIC₉₀s) of the rest of the tested fluoroquinolones were as follows: levofloxacin, 0.5 µg/ml; ciprofloxacin, trovafloxacin, and moxifloxacin, 1 µg/ml; and ofloxacin, grepafloxacin, and gatifloxacin, 2 µg/ml.

Evaluation of sitafloxacin and doxycycline
combined with rifampicin Efficacy and safety
in the treatment of non-complex brucellosis in
Chinese adults:
a real-world, multicenter comparative study



World Organisation
for Animal Health

Founded in 1924

Thank you!

Hai Jiang Ph.D
Department of Brucellosis control
National Key Laboratory of Intelligent Tracing and Forecasting for Infectious Diseases
National Institute for Communicable Disease Control and Prevention
Chinese Center for Disease Control and Prevention, Beijing, China
Phone: 010-58900767 18612892606
jianghai@icdc.cn

